COVID-19 Neurological Disease: a Global Meta-Analysis and Prospective Case Control Study in Brazil, India and Malawi.

大多数新冠肺炎患者都有咳嗽和呼吸问题。然而，我们现在也看到了患有神经(大脑)疾病的患者。我们想知道为什么要帮助我们改善治疗。1.医生正在发布关于单个或小组患者或登记表的报告。它们使用不同的定义以不同的方式描述患者。这意味着很难看到脑部疾病的全部情况。通过我们的全球网络，我们将汇集所有患者的数据(无论是否发表)，以产生一份单一的大型报告。2.我们想了解为什么有些新冠肺炎患者会患上神经系统疾病。因此，我们将在巴西、印度和马拉维进行一项研究。我们将比较患有和不患有神经系统疾病的患者，以确定神经系统疾病的危险因素。我们对那些可以治疗的因素特别感兴趣，比如血液中的缺氧。3.我们还将关注神经科患者的结果，再次关注与不良结果相关的因素。4.我们有一个强有力的病人、公众和社区参与和参与方案，并与世界卫生组织(世卫组织)和国家政策制定者建立了良好的联系。这些将有助于确保我们的信息迅速为临床指南提供信息，以改善患者管理并挽救生命。5.我们还将培训医生和科学家从事这方面的研究，提高他们的知识和技能，并建设能力。

Most patients with COVID-19 have cough and breathing problems. However, we are now seeing patients with neurological (brain) disease too. We want to understand why to help us improve treatment. 1. Doctors are publishing reports of single or small groups of patients, or registries. These describe patients in different ways using different definitions. This means it is hard to see the full range of brain disease. Through our global network, we will pull together data from all patients (published or not) to produce a single large report. 2. We want to understand why some patients with COVID-19 get neurological disease. We will therefore conduct a study in Brazil, India and Malawi. We will compare patients with and without neurological disease, to identify risk factors for neurological disease. We are especially interested in those factors which could be treated, such as lack of oxygen in the blood. 3. We will also look at outcomes for neurological patients, again looking at factors associated with a bad outcome. 4. We have a strong Patient, Public and Community Engagement and Involvement Programme, and good links to the World Health Organisation (WHO) and national policymakers. These will help to ensure our information rapidly informs clinical guidelines to improve patient management and save lives. 5. We will also train doctors and scientists in such research to improve their knowledge and skills, and build capacity.